» Articles » PMID: 23378539

A Comparison of Trends in Mortality from Primary Liver Cancer and Intrahepatic Cholangiocarcinoma in Europe

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2013 Feb 5
PMID 23378539
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To update and compare mortality from primary liver cancer (PLC) and intrahepatic cholangiocarcinoma (ICC) in Europe in 1990-2010.

Materials And Methods: We used data from the World Health Organization (WHO) to compute age-standardized (world population) mortality rates, and used joinpoint analysis to identify substantial changes.

Results: Between 2002 and 2007, PLC rates in the European Union (EU) declined from 3.9 to 3.6/100,000 men. Around 2007, the highest male rates were in France (6.2/100,000), Spain (4.9), and Italy (4.0), while the lowest ones were in Sweden (1.1), the Netherlands (1.2), and the UK (1.8). In women, mortality was lower (0.8/100,000 in 2007 in the EU), and showed more favourable trends, with a decline of over 2% per year over the last two decades as compared with 0.4% in men, in the EU. In contrast, the EU mortality from ICC increased by around 9% in both sexes from 1990 to 2008, reaching rates of 1.1/100,000 men and 0.75/100,000 women. The highest rates were in UK, Germany, and France (1.2-1.5/100,000 men, 0.8-1.1/100,000 women).

Conclusions: PLC mortality has become more uniform across Europe over recent years, with an overall decline; in contrast, ICC mortality has substantially increased in most Europe.

Citing Articles

Cross-Talk Between Tumor Cells and Stellate Cells Promotes Oncolytic VSV Activity in Intrahepatic Cholangiocarcinoma.

Neumeyer V, Chavan P, Steiger K, Ebert O, Altomonte J Cancers (Basel). 2025; 17(3).

PMID: 39941881 PMC: 11816849. DOI: 10.3390/cancers17030514.


Liver diseases: epidemiology, causes, trends and predictions.

Gan C, Yuan Y, Shen H, Gao J, Kong X, Che Z Signal Transduct Target Ther. 2025; 10(1):33.

PMID: 39904973 PMC: 11794951. DOI: 10.1038/s41392-024-02072-z.


Burden and risk factors of suspected cholangiocarcinoma in high Opisthorchis viverrini endemic rural communities in southern Lao PDR.

Homsana A, Southisavath P, Kling K, Hattendorf J, Vorasane S, Paris D PLoS Negl Trop Dis. 2024; 18(11):e0012617.

PMID: 39602377 PMC: 11602099. DOI: 10.1371/journal.pntd.0012617.


Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case.

Zhang H, Yu H Front Oncol. 2024; 14:1428370.

PMID: 39077469 PMC: 11284616. DOI: 10.3389/fonc.2024.1428370.


Small duct and large duct type intrahepatic cholangiocarcinoma reveal distinct patterns of immune signatures.

Bernatz S, Schulze F, Bein J, Bankov K, Mahmoudi S, Grunewald L J Cancer Res Clin Oncol. 2024; 150(7):357.

PMID: 39034327 PMC: 11271402. DOI: 10.1007/s00432-024-05888-y.